Radcliffe Capital Management
CLDI icon

Radcliffe Capital Management’s Calidi Biotherapeutics CLDI Stock Holding History

Radcliffe Capital Management’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-209
Closed -$3.98M – 1193
2022
Q2 		$3.98M Hold
209
– – 0.09% 373
2022
Q1 		$3.96M Buy
209
+1
+0.5% +$18.9K 0.09% 351
2021
Q4 		$3.93M Buy
+208
New +$3.92M 0.1% 288

Other funds holding CLDI

Driehaus Capital Management
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Polar Asset Management Partners
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
First Trust Capital Management
First Trust Capital Management Chicago, Illinois $1.72B AUM 70.66% 1-Year Est. Return
Woodline Partners
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Shaolin Capital Management
Shaolin Capital Management Miami, Florida $2.1B AUM 64.05% 1-Year Est. Return
Spartan Fund Management
Spartan Fund Management Toronto, Ontario, Canada $30M AUM 11.98% 1-Year Est. Return
Logan Stone Capital
Logan Stone Capital Chicago, Illinois $473M AUM 0.79% 1-Year Est. Return
Highbridge Capital Management
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $1B AUM 29.68% 1-Year Est. Return

Radcliffe Capital Management's CLDI Position: Q3 2022 in Review

Radcliffe Capital Management sold out of Calidi Biotherapeutics (CLDI) in Q3 2022, closing a stake of 209 shares — an estimated $3.98M sold.

Radcliffe Capital Management first reported a position in CLDI in Q4 2021 and held it in 3 quarters. The position peaked at $3.98M in Q2 2022. 20 funds tracked by Wall St. Rank hold CLDI as of Q3 2022.

  • Radcliffe Capital Management reported no remaining Calidi Biotherapeutics position as of Q3 2022 after selling out during the quarter.
  • Radcliffe Capital Management sold 209 Calidi Biotherapeutics shares in Q3 2022, an estimated $3.98M.
  • Radcliffe Capital Management first reported a position in Calidi Biotherapeutics in Q4 2021 and held it in 3 quarters.
  • Radcliffe Capital Management's Calidi Biotherapeutics position peaked at $3.98M in Q2 2022.
  • 20 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q3 2022.

Based on Radcliffe Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.